✦ LIBER ✦

39 Topotecan versus treosulfan in recurrent ovarian cancer after initial chemotherapy with platinum and paclitaxel. a prospective randomised phase III study of the AGO ovarian cancer study group

✍ Scribed by S. Loibl; W. Meier; A. du Bois; W. Kuhn; J. Pfisterer; R. Kimmig; S. Olbricht; B. Richter

Book ID: 118620215
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 163 KB
Volume: 1
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(03)90073-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Topotecan versus treosulfan, an alkylati

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

✍ Werner Meier; Andreas du Bois; Alexander Reuss; Walther Kuhn; Sigrid Olbricht; M 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 545 KB

Role of salvage chemotherapy with topote

Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study

✍ Ghamande, Sharad A.; Piver, M. Steven 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

## Background and Objectives: We assessed the role of salvage chemotherapy with topotecan and cisplatin in patients with platinum-and paclitaxel-resistant advanced and recurrent ovarian or primary peritoneal cancer, based on the reported in vivo and in vitro synergism between these two drugs. Meth

Impact of age on outcome in patients wit

Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

✍ Pauline Wimberger; Nils Lehmann; Rainer Kimmig; Alexander Burges; Werner Meier; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 226 KB

Topotecan and carboplatin in patients wi

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

✍ Dominique Koensgen; Dirk Stengel; Antje Belau; Peter Klare; Guelten Oskay-Oezcel 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 324 KB

36 Paclitaxel/Carboplatin(TC) vs Paclita

36 Paclitaxel/Carboplatin(TC) vs Paclitaxel/Carboplatin sequentially followed by Topotecan (TC-Top) in first-line treatment of ovarian cancer Flgo stages IIB – IV interim results of a gynaecologic cancer intergroup phase III trial of the Ago ovarian cancer study group and Gineco

✍ E. Pujade-Lauraine; J. Pfisterer; A. Lortholary; R. Kimmig; B. Weber; A. du Bois 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Neuroprotection with amifostine in the f

Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group

✍ F. Hilpert; A. Stähle; O. Tomé; A. Burges; D. Rossner; K. Späthe; V. Heilmann; B 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 185 KB